Novo Nordisk Plunges 8% After Weak 2030 Outlook — Wall Street Overreaction or Patent Cliff Panic?

Novo Nordisk shares just plummeted 8% after management’s Capital Markets Day left Wall Street underwhelmed by its growth targets through 2030. Despite trading at a bargain P/E of 9.7 with a solid 4% dividend yield, investors panicked over the upcoming 2032 Wegovy and Ozempic patent cliff, slowing prescription growth, and mounting competition from Eli Lilly. In this episode of Implied, we break down whether this steep selloff is an emotional Wall Street overreaction that creates a classic value entry point—or a warning that the pharma giant’s explosive growth era is coming to an end. Tune in for the full story behind the drop!